Gilead Sciences heads into its August 4 Q2 print with options traders at their most bullish in a year and the Street sending conflicting signals on valuation.
The clearest read this week is in the options market. The put/call ratio has dropped to 0.40 — its lowest reading of the past 52 weeks and more than a standard deviation below the 20-day average of 0.43. That is a notably call-heavy posture for a stock approaching earnings, and it sits in sharp contrast to the hedging posture that typically builds ahead of a print. The stock itself has added 3.1% on the week to close at $134.32, part of a broader biotech lift — close peer AMGN rose 7.3% and HALO added 6.2% over the same stretch, suggesting the sector tailwind is real rather than GILD-specific.
Short interest tells a deliberately quiet story here. At just over 2% of the free float, bears have little conviction in the name. The position has drifted about 1% lower on the week and nearly 2% lower over the past month, a slow bleed rather than any decisive covering move. Borrow costs are negligible at 0.32%, and availability is essentially unconstrained — the lending market carries no squeeze tension whatsoever. This is not a stock where the short side is making an argument.
The trickier picture is on the Street. The direction of recent analyst moves has been downward. Leerink Partners downgraded GILD to Market Perform last week, cutting the target to $127 from $146 — a notable shift from a firm with a strong biotech franchise. Barclays, just this morning, trimmed its target to $145 from $155 while holding Equal-Weight. Morgan Stanley, still Overweight, nudged its target marginally lower to $165. The mean consensus target sits at $157, implying roughly 17% upside from current levels — but the direction of travel is target compression, not expansion. The PE multiple has contracted about 3 points over the past 30 days to 25.9x, and EV/EBITDA has eased modestly too, suggesting the market has been quietly re-rating the stock even as the price has climbed. The 30-day EPS momentum score ranks in the 95th percentile, but the 90-day figure sits near the bottom of the universe at the 8th percentile — short-term estimate revisions have turned positive, while the longer horizon remains under pressure.
Insider activity adds a modest note of caution. CEO Daniel O'Day sold approximately $1.9 million of stock across two transactions in early July, while CFO Andy Dickinson and Chief Commercial Officer Johanna Mercier each sold smaller amounts around mid-July. The trades are low significance individually, but the pattern is consistent one-way selling across multiple senior executives over the past 45 days. Net insider activity over 90 days shows a positive share count only because of an equity award to O'Day in June, not open-market buying.
The previous earnings print on May 7 produced a 3.6% one-day decline and a 3.1% five-day decline — a reminder that GILD's earnings releases have not reliably rewarded buyers. The August 4 report is therefore the immediate test of whether the bullish options positioning and rising stock price reflect genuine fundamental momentum or an overcrowded pre-earnings trade in a sector that happened to have a good week.
See the live data behind this article on ORTEX.
Open GILD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
